Interactions between serum FSH, inhibin B and antral follicle count in the decline of serum AMH during the menstrual cycle in late reproductive age

David M. Robertson1,2 | Chel Hee Lee3 | Angela Baerwald4

Abstract
Objective: To investigate the hormonal interrelationships during the menstrual cycle in women of late reproductive age with suppressed serum AMH and antral follicle count (AFC).

Methods: Serum hormones (AMH, FSH, LH, estradiol, progesterone, inhibin A, inhibin B), AFC (2-10 mm) and AMH/AFC ratio (an estimate of AMH/follicle) were assessed every 2-3 days across the menstrual cycle in 26 healthy ovulatory women aged 18-50 years.

Results: An 11-fold fall in AMH/AFC was observed in women aged ≥45 years compared to those 18-45 years (P < .001). Although women ≥45 years exhibited normal menstrual cycle patterns of serum estradiol, progesterone, LH and inhibin A, FSH was elevated (P < .001) and inhibin B suppressed (P < .001) compared to the younger group. Overall FSH was inversely correlated (r = .55, P < .05) and AMH directly correlated (r = .70, P < .01) with AFC across both high and low AMH/follicle groups.

Conclusions: It is hypothesized that the marked fall in AMH/follicle in late reproductive age is attributed to the change in the hormonal interplay between the pituitary and ovary. The fall in AFC leads to a decrease in inhibin B and a concomitant increase in FSH by a recognized feedback mechanism. It is postulated the elevated FSH suppresses AMH either directly or indirectly through oocyte-specific growth factors leading to a marked fall in AMH/follicle. We propose that pituitary-ovarian and intra-ovarian regulatory systems underpin the accelerated fall in AMH/follicle during the transition to menopause.

Keywords
BMP15, cumulin, estradiol, GDF9, inhibin A, menopause, oocytes
INTRODUCTION

It is recognized that the decline in ovarian reserve approaching menopause is complex, with a number of mathematical models developed to describe the decline.1,2 Faddy1 described the decrease in ovarian reserve as a combination of an increase in atresia of the primordial follicle pool and a decreased progression of resting follicles into the growing follicle pool leading to an accelerated late decline. AMH has been viewed as a key contributor to this decline, as AMH is known to suppress both primordial pool atresia and follicular progression, at least in mice.3-7

The interplay between AMH, FSH, antral follicle count (AFC) and antral follicle growth dynamics is not fully understood. AMH was shown to inhibit FSH-stimulated follicle growth, aromatase activity, LH receptor levels and prostegesterone synthesis in mice and humans.8-10 These data suggested that in the absence of AMH, follicle development and steroid hormone production were more sensitive to FSH.5,6 Visser10 postulated that when AMH is decreased, the FSH-dependent stages of folliculogenesis (ie the growth of small to large antral follicles) become more sensitive to FSH and more follicles are permitted to advance to the dominant phase. Conversely, ovarian reserve in mice was conserved by AMH administration.11

Both stimulatory and inhibitory effects have been reported in the regulation of AMH by FSH. In a review of human in vivo studies, serum AMH declined following exogenous FSH, and GnRH agonist/antagonist treatment.12,13 Van Heldin14 investigated the changes in serum FSH and AMH in adult women following a GnRH bolus and showed a 53% increase in serum FSH within 30 minutes, followed by a 60% decrease in serum AMH by 90 minutes. This response was rapid and possibly direct without involving possible growth factor intermediaries. Roy15 showed a marked (>10-fold) elevation of ovarian AMH mRNA in FS Hồβ−/−/infertile mice compared to wild-type or FSHβ−/−/FS HồβWT controls, supporting the inhibitory role of FSH on AMH expression in this system. Conversely, stimulatory effects of FSH on AMH have been observed in vitro cultures of human and monkey follicles; however, whether the FSH effect was direct or indirect through intermediaries was not established.16,17

There is evidence that AMH is under stimulation by a range of growth factors (BMP-2, -6, -7, -15, GDF9)18,19 two of which are oocyte-specific (BMP15 and GDF9),20,21 BMP15 and GDF9 regulate granulosa cell proliferation and gonadotropin-induced function probably as a heterodimer, cumulin,22-24 BMP15 and GDF9 have been shown to stimulate AMH both in vitro18,19 and in vivo,22 although their in vitro actions on AMH are inhibited by FSH.25,26 It has been postulated25 that these growth factors and AMH exert a paracrine role in regulating FSH sensitivity and thus follicle recruitment. In summary, AMH is regulated by FSH, both directly and indirectly through oocyte-specific growth factors.

Variability in menstrual cyclicity is observed with age. While the ovarian reserve is reduced in late reproductive life, most women exhibit normal menstrual cycles with many similar attributes to those of younger women in terms of cyclicity, ovulation and steroid hormone profiles.25-29 These parameters typically change once the perimenopausal period is initiated, as reflected in oligomenorrhea, polymenorrhea, anovulation, aberrant folliculogenesis and atypical transient elevations in estradiol.27 In contrast, some women maintain normal cyclic behaviour up until close to menopause.25,28,29

In earlier detailed studies,28,29 women of mid (aged 18-35, n = 10) and late (45-50, n = 16) reproductive age with regular ovulatory menstrual cycles were assessed every 2-3 days across one interovulatory interval (IOI). Serum reproductive hormones, antral follicle count (AFC), antral follicular growth dynamics, luteal growth dynamics and endometrial growth dynamics were characterized across the IOI. Age-related changes in the presence of luteal phase dominant follicles,28,29 endometrial thickness,30 luteal growth31 and interrelationships between ovarian and pituitary hormones32 have been reported. The relationships between aberrant follicular dynamics, AFC and hormone production as women transition to menopause require further investigation.

It is well known26,27 that serum AMH, inhibin B and AFC decrease in late reproductive age, as the ovarian reserve is depleted. Serum AMH is used as a clinical marker of ovarian reserve in the treatment of infertility.12,13 AMH and inhibin B are products of the follicle. It is thought that the decrease in AMH with age was attributed to an overall decrease in the number of antral follicles. If this is the case, one would anticipate that the ratio of AMH and inhibin per follicle would remain unchanged with age. However, preliminary data from our laboratory have suggested a dramatic fall in the ratio of AMH/AFC late in reproductive life, far greater than that experienced by AMH or AFC alone.

The objective of this study was to characterize the hormonal relationships associated with the fall in AMH/AFC in late reproductive age. To this end, the interrelationships between AFC, AMH, FSH, LH, estradiol, progesterone, inhibin A and inhibin B were examined during the late reproductive age using data from a previously described study.29 AMH levels were expressed as serum AMH concentration and a ratio of serum AMH concentration/AFC 2-10 mm. We tested the hypothesis that the marked fall in serum AMH with advanced reproductive age was attributed to a decrease in AMH levels/follicle and that this decrease in AMH/follicle was attributed to the action of key reproductive hormones (FSH, inhibin B).

METHODS

2.1 | Subjects and methods

A novel set of experiments and statistical analyses were conducted using data obtained from a previous study to characterize age-related changes in ovarian antral follicle dynamics.29 The study protocol was approved by the Biomedical Research Ethics Board at the University of Saskatchewan, and the Strategic Priorities and Planning Committee of the Saskatoon Health Region. Study
procedures were conducted in accordance with the Tri-Council Policy Statement on the Ethical Conduct for Research Involving Humans.

Details of subject recruitment and basis for inclusion in the study are outlined previously. Women of mid reproductive age group (18-35 years, n = 10) and advanced reproductive age group (45-50 years, n = 16) were evaluated. Women were eligible if they had a history of regular ovulatory menstrual cycles (ie 21-45 days long). Women with anovulatory cycles were excluded. Transvaginal ultrasonography was conducted as outlined previously. Scans were initiated in the early-mid follicular phase and continued every 1-3 days for one complete interovulatory interval (IOI). An IOI was defined as the interval from one ovulation to the subsequent ovulation. The AFC for different diameter categories (ie 2-3, 2-5, 2-10, ≥3 and ≥6 mm) was quantified using serial transvaginal ultrasonography every 1-3 days across the IOI, by a single investigator, as previously described. AFC data for follicles 2-5 and 2-10 mm were examined in this study. The follicular phase was defined as the period from the first day of menses until the last day the preovulatory follicle was observed. The luteal phase was defined as the period from the day of ovulation until the day before the first day of menses. Blood samples were collected every 2-3 days during the IOI. Serum hormone levels (FSH, LH, estradiol, progesterone, inhibin A, inhibin B, AMH (24/32, Anshlabs)) were analysed as previously described. To explore the relationship between AMH and AFC in late reproductive age, a highly sensitive AMH ELISA was devised which was able to detect AMH in 95% of samples including those in late reproductive age.

Data were combined into 3-day bins for each participant across the IOI as follows: late follicular phase 1; early, mid-late, late and very late luteal phase; menses; and early, mid and late follicular phase (LFP1, ELP, MLP, LLP, VLLP, M, EFP, MFP, LFP2).

2.2 | Statistics

Based on the AMH/AFC ratio data distribution with age, two groups <=45 vs >45 years were visually identified. A subsequent division into two low and high ratio groups (LRG and HRG) was statistically made, justified using a logistic regression method that maximized the separation between the two age groups. Comparison of hormone levels between stages of the menstrual cycle within the low and high AMH/AFC ratio groups was assessed by an unpaired t test with unequal variance and by repeated measure ANOVA (mixed-effect model) to assess interactions (SAS 9.4). Pearson correlation coefficients were used throughout.

3 | RESULTS

Hormone and AFC data were obtained every 2-3 days across the IOI. The data were then averaged across the luteal phase, the follicular phase and across the IOI. AFC data used in the analyses included all detectable follicles (2-5 and 2-10 mm) in each phase and combined phases.

3.1 | Changes in serum AMH, AFC and AMH/AFC with age

Serum AMH and AFC (2-10 mm) averaged across the IOI decreased with advancing age (Figure 1). When expressed as a ratio of AMH/AFC (an estimate of AMH/follicle), a dramatic fall was observed in 12 of 16 women in the >45 years group, reduced in individual cases to values ~1% of those in women <45 years of age. Based on this marked change in AMH/AFC ratios with age, two groups (11-fold difference (P < .001, Table 1, Figure 1) were identified and designated as high AMH/AFC ratio (HRG, n = 14) and low AMH/AFC ratio (LRG, n = 12) groups. No change in inhibin B/AFC ratio was observed between HRG and LRG (Figure 1, Table 1) across the same age groups.
Determination of AMH/AFC using AFC (2-5 mm) showed similar changes to that seen with AMH/AFC (2-10 mm) (Table 2).

### 3.2 | Changes in AFC and hormone levels across the IOI in HRG vs LRG

No differences in the mean length of the IOI, follicular and luteal phases and day of onset of menstruation, were observed between HRG and LRG (Tables 1 and 2). In the HRG, mean AMH/AFC was 18% higher (P = .039) in the follicular vs luteal phase; otherwise, no difference between follicular and luteal phases within groups was detected (Table 2).

Serum reproductive hormones levels were pooled into 3-day bins across the IOI and compared between HRG and LRG (Figure 2). Patterns of serum LH, estradiol, Inhibin A and progesterone across the IOI remained unchanged between groups. However, in the LRG, differences in FSH and inhibin B were noted.
4 | DISCUSSION

The availability of detailed analyses of reproductive status, hormones and AFC in asymptomatic women across the menstrual cycle with age provides us with the means to examine the underlying relationships between changes in follicle number and reproductive hormones.

In this study, we have demonstrated that although both serum AMH and AFC decrease with age, there is a dramatically exaggerated fall in AMH/AFC in older (>45 years) women. This decrease in AMH/AFC can fall to ~1% of values observed in younger women. To explore further, data were divided into two groups (high vs low AMH/AFC) and hormonal patterns and cyclicity were evaluated. Our findings show that ovulatory women in late reproductive life with low AMH levels per follicle demonstrate normal ovarian function as assessed by normal menstrual cycle characteristics, such as length of follicular and luteal phases and day of menstruation. In addition, serum LH, estradiol, inhibin A and progesterone were unchanged. Major changes, however, were noted with elevated FSH and suppressed inhibin B associated with low antral follicle count.

From these findings, we posed the following question: Is there any relationship between the marked fall in AMH/follicle with age and the change in interrelationships between FSH and inhibin B? We hypothesized that the marked fall in serum AMH in advanced reproductive age women is attributed to changes in the interplay of AFC, serum FSH and inhibin B and possibly ovarian oocyte-specific growth factors.

In Figure 4 and Table 3, we present a schematic diagram as the basis of our hypothesis, linking the changes of AMH/AFC with changes in serum FSH and inhibin B:

Step 1. Relationship between number of antral follicles and Inhibin B: Mean cycle inhibin B levels are directly proportional ($r = .70$, $P < .01$) to AFC across all ages (Figure 3C).

Step 2. Relationship between Inhibin B and FSH: At low AFC, inhibin B levels are low while serum FSH is elevated by the known feedback mechanism of inhibin B on pituitary FSH ($r = -.55$, $P < .01$) Figure 3A).

| Table 2: Antral Follicle Count (2-5 and 2-10 mm), Serum AMH and AMH/follicle Ratio in the Follicular and Luteal Phases of Menstrual Cycles in High and Low AMH/follicle Ratio Groups |
| --- |
| **Group** | **Number of Subjects** | **Phase of Cycle** | **AMH (ng/mL)** | **AMH (pg)/AFC** |
| High AMH/AFC (HRG) | 14 | Luteal | 3.73 ± 2.57 | 43.317 ± 0.8 |
| | | Follicular | 4.22 ± 3.01 | 39.9 ± 18.3 |
| | | P value | .68 | .62 |
| Low AMH/AFC (LRG) | 12 | Luteal | 0.142 ± 0.140 | 15.6 ± 6.81 |
| | | Follicular | 0.120 ± 0.098 | 16.3 ± 5.62 |
| | | P value | .52 | .6 |
| | | LP vs LP | P value | .000 |
| | | FP vs FP | P value | .000 |

Note: Mean ± SD. *P < .05.
FIGURE 2  Profiles of mean serum hormones across the menstrual cycle in women that were divided into two groups based on average AMH levels/follicle (open columns, high AMH/AFC ratio (HRG); closed columns, low AMH/AFC ratio (LRG)). Serum estradiol, progesterone, AMH, antral follicle count (AFC, 2-10 mm) and ratios of AMH/AFC and inhibin B/AFC are presented. Serum sample values have been averaged in 3-d groups across the intra-ovulatory interval between ovulations (OV1 and OV2) as follows: LFP1, late follicular phase, ELP, MLP, LLP, VLLP (early, mid-late, very late luteal phase); M, menses EFP, MFP, LFP2, early, mid-late follicular phases.
Step 3. Relationship between FSH and AMH: It is postulated that in the older women with low AMH/follicle, high FSH inhibits AMH either directly and/or indirectly through oocyte-specific growth factor-mediated regulation of AMH. GDF9/BMP15 are the most likely growth factors responsible, as they are oocyte specific and their stimulatory effects on AMH are inhibited by FSH in vitro. A direct inhibitory effect of FSH on AMH is also likely.

Conversely, at higher AFC, inhibin B is elevated, FSH is suppressed, and AMH levels/follicle are elevated.

In a previous study based on multiple linear regression analysis, it was concluded that the decrease in serum AMH with age in

**TABLE 3 Correlation coefficients of relationships between serum hormones and antral follicle count (AFC) presented graphically in Figure 3 and the text**

| Regression analysis | Correlation coefficient | $P$ value | Figure | Figure 4 Step |
|---------------------|-------------------------|-----------|--------|--------------|
| Inhibin B vs AFC    | $r = +.70$              | $<.01$    | 3C     | 1            |
| FSH vs inhibin B    | $r = -.47$              | $<.01$    | 3E     | 2            |
| FSH vs AMH          | $r = -.53$              | $<.01$    | 3D     | 3            |
| AMH vs AFC          | $r = +.88$              | $<.01$    | 3B     |              |
| FSH vs AFC          | $r = -.55$              | $<.01$    | 3A     |              |
| Inhibin B vs AMH    | $r = +.80$              | $<.01$    |        |              |
33 There is evidence that inhibin B rises with follicles identified. The basis for this delayed rise in inhibin B is unclear. It is recognized that antral folliculogenesis across the normal menstrual phase wave. This delay in inhibin B secretion was correlated with elevated serum FSH to decreased AFC and thus decreased inhibin B and not to decreased AMH. The inverse relationship between AMH and FSH is attributed to the concomitant decrease in AMH as a result of either putative oocyte growth factor-induced synthesis inhibited by elevated FSH or to an independent inhibitory action of FSH.

It is interesting to note that the rise in serum inhibin B in the luteal-follicular phase transition of the menstrual cycle was delayed by an average of 4 days in women with low AMH/follicle compared to high AMH/follicle. This delay in inhibin B secretion was correlated with AFC as the largest delay was observed in women with the lowest AFC. The basis for this delayed rise in inhibin B is unclear. It is recognized that antral folliculogenesis across the normal menstrual cycle consists of a series of follicle waves, with two or three waves of follicles identified. There is evidence that inhibin B rises with the recruitment of a follicle wave at the time of selection of the dominant follicle. It is possible that the delayed rise in inhibin B reflects an additional follicle wave preceding the ovulatory follicular phase wave. One consequence of the delay in inhibin B rise is that serum FSH is elevated for an additional period in the follicular phase, contributing, at least in part, to the overall elevated follicular phase FSH in late reproductive age.

It has been previously shown that there is a higher incidence of cycles with luteal phase dominant follicles (LPDF) in women of advanced reproductive age compared to younger women which can lead to significantly elevated serum E2 levels in the luteal phase. Examination of the present data, 5/14 women in the HRG and 8/12 women in LRG had LPDF cycles. These data indicate that the difference in AMH/follicle between high and low AMH/follicle groups is not attributed to the presence of LPDFs, as LPDF cycles are found in both groups.

Based on the close association between AFC and serum AMH, a number of studies have explored the diagnostic use of serum AMH to forecast the onset of menopause and likely end of natural fertility. However, based on a large meta-analysis, the predictive value of AMH at an individual basis has been questioned. One particular problem identified in the report was that AMH is less effective in predicting menopause when assessing older women. Based on the present study, it is postulated that the marked change in AMH/follicle approaching menopause, which is in part age-related, is a contributing factor to the reduced reliability of AMH as a marker of ovarian reserve for assessing the onset of menopause. Future studies should be conducted to evaluate the utility of AMH/AFC as a marker for predicting the onset of menopause.

In summary, based on these findings, we propose that the rapid decline in AMH in late reproductive age is attributed to a concomitant elevation of FSH, which either inhibits AMH directly or inhibits the putative oocyte growth factor-mediated synthesis of AMH. The elevated FSH is due to a reduction in pituitary feedback by the low inhibin B levels associated with the low AFC at this stage. The reduced size of the ovarian reserve appears to be the key factor, which drives these changes. Further elaboration of this hypothesis awaits the development of suitably sensitive immunoassays for serum and follicular fluid GDF9/BMP15 to confirm their central role. Future work in this area may provide insight into the utility of quantifying AMH/follicle to provide an indication of impending loss of fertility and anticipated response to treatment in women undergoing ovarian stimulation and IVF/embryo transfer.

ACKNOWLEDGEMENTS

The authors would like to acknowledge the women who volunteered to participate in this study. We would further like to thank Dr Roger Pierson for assistance in providing imaging equipment, Ms Heidi Vanden Brink who assisted with data collection and Sue Panckridge for assistance with the art work. Drs W. Ledger and R. McLachlan are
thanked for providing feedback on the study. There are no conflicts of interest related to the publication of this manuscript.

CONFLICT OF INTEREST
The authors have nothing to disclose.

AUTHOR CONTRIBUTIONS
Each author contributed equally to the study.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from both authors. The data are not publicly available due to privacy or ethical restrictions. It should be noted that all files are permanently archived in the research laboratory of Dr Angela Baerwald, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

ORCID
David M. Robertson https://orcid.org/0000-0002-5527-9825

REFERENCES
1. Faddy MJ. Follicle dynamics during ovarian ageing. Mol Cell Endocrinol. 2000;163:43-48.
2. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH. A validated model of serum anti-mullerian hormone from conception to menopause. PLoS One. 2011;6:e22024.
3. Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update. 2014;20:370-385.
4. Durlinger AL, Kramer P, Karels B, et al. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology. 1999;140:5789-5796.
5. Durlinger AL, Gruijters MJ, Kramer P, et al. Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001;142:4891-4899.
6. Visser JA, Durlinger AL, Peters UJ, et al. Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-Mullerian hormone null mice. Endocrinology. 2007;148:2301-2308.
7. Dewailly D, Robin G, Peigne M, Decanter C, Pigny P, Catteau-Jonard S. Interactions between androgens, FSH, anti-Mullerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary. Hum Reprod Update. 2016;22:709-724.
8. Grossman MP, Nakajima ST, Fallat ME, Slow Y. Mullerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertil Steril. 2008;89:1364-1370.
9. Pellatt L, Rice S, Dilaver N, et al. Anti-Mullerian hormone reduces follicle sensitivity to follicle-stimulating hormone in human granulosa cells. Fertil Steril. 2011;96:1246-1251.
10. Visser JA, Themmen AP. Role of anti-Mullerian hormone and bone morphogenetic proteins in the regulation of FSH sensitivity. Mol Cell Endocrinol. 2014;382:460-465.
11. Kano M, Sosulski AE, Zhang L, et al. AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy. Proc Natl Acad Sci USA. 2017;114(9):E1688-E1697.
12. Weintraub A, Margalioth EJ, Chetrit AB, et al. The dynamics of serum anti-Mullerian-hormone levels during controlled ovarian hyperstimulation with GnRH-antagonist short protocol in polycystic ovary syndrome and low responders. Eur J Obstet Gynecol Reprod Biol. 2014;176:163-167.
31. Baerwald A, Vanden Brink H, Hunter C, et al. Age-related changes in luteal dynamics: preliminary associations with antral follicular dynamics and hormone production during the human menstrual cycle. *Menopause*. 2018;25:399-407.

32. Robertson DM, Lee CH, Baerwald A. Interrelationships among reproductive hormones and antral follicle count in human menstrual cycles. *Endocr Connect*. 2016;5:98-107.

33. Baerwald AR, Adams GP, Pierson RA. A new model for ovarian follicular development during the human menstrual cycle. *Fertil Steril*. 2003;80:116-122.

34. Ginther OJ, Beg MA, Bergfelt DR, Donadeu FX, Kot K. Follicle selection in monovular species. *Biol. Reprod*. 2001;65:638-647.

35. van Disseldorp J, Faddy MJ, Themmen AP, et al. Relationship of serum antimullerian hormone concentration to age at menopause. *J Clin Endocrinol Metab*. 2008;93:2129-2134.

36. Robertson DM, Kumar A, Kalra B, et al. Detection of serum antimullerian hormone in women approaching menopause using sensitive anti-mullerian hormone enzyme-linked immunosorbent assays. *Menopause*. 2014;21:1277-1286.

37. Depmann M, Eijkemans MJ, Broer SL, et al. Does AMH relate to timing of menopause? Results of an individual patient data meta-analysis. *J Clin Endocrinol Metab*. 2018. https://doi.org/10.1210/jc.2018-00724. Online ahead of print.

How to cite this article: Robertson DM, Lee CH, Baerwald A. Interactions between serum FSH, inhibin B and antral follicle count in the decline of serum AMH during the menstrual cycle in late reproductive age. *Endocrinol Diab Metab*. 2021;4:e00172. https://doi.org/10.1002/edm2.172